Clinical Trial - NCT02908451

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

Recruiting

Sponsor: AbGenomics B.V Taiwan Branch

Collaborators:

Information provided by (Responsible party): Sponsor

ClinicalTrials.gov Identifier: NCT02908451

Protocol Info

Short Description: Phase I of ABGN-107 in Locally Adv., Recurrent, or Met. Gastric, Colorectal, or Pancreatic Cancer
Long Description: A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer.
MGH Status: Open
Sponsor: AbGenomics
Disease Program: GI

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
Condition Title Intervention Phase
Gastric Cancer Colorectal Cancer Pancreatic Cancer Biliary Cancer AbGn-107 Phase 1
Study Type Interventional
Official Title A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

Primary Outcome Measures

Adverse events (AEs) graded according to CTCAE v4.03. [Time Frame: 28 days] [Designated as safety issue: ]


Secondary Outcome Measures

Cmax (maximum measured concentration of the analyte in plasma) [Time Frame: 70 days after treatment] [Designated as safety issue: ]

Tmax (time from dosing to maximum measured concentration) [Time Frame: 70 days after treatment] [Designated as safety issue: ]

T1/2 (half-life of the analyte) [Time Frame: 70 days after treatment] [Designated as safety issue: ]

Immunogenicity evaluation based on anti-drug antibodies titer [Time Frame: 70 days after treatment] [Designated as safety issue: ]

Overall Response Rate Evaluated by Response Evaluation Criteria in Solid Tumor (RECIST) [Time Frame: Every 8 weeks up to 2 years from the first patient enrolled] [Designated as safety issue: ]

Estimated Enrollment: 116
Study Start Date: April 2017
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: October 2020
Arms Assigned Interventions

Experimental:AbGn-107

AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
Biological:AbGn-107
Antibody Drug Conjugate

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

Inclusion Criteria:

1. Age ≥18 years. A patient may be of either sex and of any race/ethnicity.

2. Histologically confirmed, chemo-refractory, locally advanced, recurrent or metastatic gastric (including GE junction), colorectal, or pancreatic adenocarcinoma or biliary cancer (including cholangiocarcinoma, gallbladder and ampullary carcinomas).

1. Patient must not have curative options available (e.g. a single metastatic focus in the liver in a patient with MCRC eligible for metastasectomy).

2. Chemo-refractory is defined as:

  • Progression on or following, or intolerant of, at least one prior line of standard systemic therapy for advanced or metastatic gastric or pancreatic or biliary cancers.
  • Progression on or following, or intolerant of, at least two prior lines of standard systemic therapy for advanced or metastatic colorectal cancers.
  • Patients who have progressed/recurred following neoadjuvant/adjuvant chemotherapy for earlier stage disease, if completed within the previous 6 months, are eligible.

3. Archived tissue must be available for all patients (both dose escalation and expansion cohorts). Dose Escalation Only-If tissue is not available, patients may still be considered eligible for enrollment, if all other eligibility criteria are confirmed and after discussion with and approval by the sponsor medical monitor. Cohort Expansion Only-Tissue must be to confirmed positive for expression of AG7 antigen during the Pre-Screening period, defined as proportional score ≥2, via slides or tumor block from either original diagnostic biopsy material or biopsy of relapsed disease,prior to enrollment.

4. Measurable disease by RECIST 1.1 criteria

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.

6. Adequate organ function within 3 weeks prior to first study drug administration as evidenced by:

1. Absolute neutrophil count ≥1.5 x 10^9/L,

2. Hemoglobin ≥9 g/dL,

3. Platelet count ≥100 x 10^9/L,

4. Serum creatinine ≤1.5 x upper limit of normal (ULN) or a calculated creatinine clearance >60 mL/min,

5. Total bilirubin <1.5 x ULN, except for patients with Gilbert's disease who are eligible if total bilirubin ≤ 3 mg/dL.

6. Aspartate aminotransferase (AST)/serum glutamic-oxalacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <2.5 x ULN, or, in the presence of documented liver metastases, ≤5 x ULN.

7. Ability to adhere to dose and visit schedules.

8. Women of childbearing potential (WOCP) must have a negative pregnancy test result prior to enrollment. WOCP and men whose partners are WOCP must agree to use a highly effective method of birth control during the study and for 6 months following the last dose of study drug. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).

9. Ability to provide written informed consent

10. Life expectancy of at least 3 months.

Exclusion Criteria:

1. Any persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 drug-related toxicity (except alopecia, erectile impotence, tinnitus, hot flashes, and loss of libido) associated with previous treatment. Inclusion of patients with persistent neuropathy or hearing loss Grade ≥2 due to previous treatment requires discussion with the sponsor.

2. Radiation therapy within 2 weeks prior to first study drug administration.

3. Major surgery within 3 weeks prior to first study drug administration.

4. Any chemotherapy within 30 days of enrollment.

5. Participation in any other clinical study with a potentially therapeutic agent or receipt of another investigational product within 21 days or 5 plasma half-lives, whichever is longer, prior to first day of drug administration (Day 1).

6. Active central nervous system metastases. Patients with a history of brain metastases may be eligible, provided they have been definitively treated and are clinically stable, after discussion with sponsor. Treated or untreated leptomeningeal disease is not permitted.

7. Known human immunodeficiency virus (HIV) infection or a known HIV-related malignancy. Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.

8. Known active hepatitis B or C. HBV and HCV tests are required prior to Day 1.

9. Any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would impair with their ability to receive or tolerate the planned treatment, or interfere with the study evaluations or optimal participation in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02908451

Locations

  • United States, Arizona
    • Mayo Clinic Phoenix, Arizona, United States, 85054
  • United States, California
    • University of California San Francisco, California, United States, 94143
  • United States, Massachusetts
    • Massachusetts General Hospital Boston, Massachusetts, United States, 02114
    • Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215
    • Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215
  • United States, Washington
    • University of Washington, Seattle Cancer Care Alliance Seattle, Washington, United States, 98109
  • Taiwan,
    • China Medical University Hospital Taichung, , Taiwan, 404
    • National Cheng Kung University Hospital Tainan, , Taiwan, 48
    • National Taiwan University Hospital Taipei, , Taiwan, 100

Sponsors and Collaborators

AbGenomics B.V Taiwan Branch

More Information

No publications provided

Responsible Party: Sponsor
ClinicalTrials.gov Identifier: NCT02908451
Other Study ID Numbers:
Study First Received:
Last Updated:
Health Authority:

Keywords provided by AbGenomics B.V Taiwan Branch:

Cancer

Antibody Drug Conjugate

AbGn-107

Adenocarcinoma

Gastric

Colorectal

Pancreatic

biliary

cholangiocarcinoma

gallbladder

ampullary carcinomas

Additional relevant MeSH terms:

Colorectal Neoplasms

Pancreatic Neoplasms

Biliary Tract Neoplasms

Immunoconjugates

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on August 15, 2019